The DOI matches its Crossref record.
Abnormalities of endocrine function in patients with clinically silent adrenal masses.
Abstract
Ambrosi B, Peverelli S, Passini E, Re T, Ferrario R, Colombo P, Sartorio A, Faglia G. Abnormalities of endocrine function in patients with clinically "silent" adrenal masses. Eur J Endocrinol 1995;132:422–8. ISSN 0804–4643 Because, in recent years, patients with incidentally discovered adrenal masses have been encountered increasingly, their endocrine function was investigated in basal conditions and after dynamic tests. Thirty-two patients (23 women and 9 men, aged 28–74 years) were studied. Lesion diameter, as documented by computed tomography and/or nuclear magnetic resonance imaging, ranged between 5 and 65 mm; the tumors were localized on the right in 22 patients, on the left in 5 and bilaterally in 5 cases. In basal conditions, urinary free cortisol (UFC) excretion, plasma adrenocorticotropin (ACTH) and cortisol levels were normal, except for 4 patients who showed high UFC and ACTH levels in the low–normal range. Ovine corticotropin-releasing hormone (CRH, 1 μg/kg iv) was given to 18 patients, inducing normal ACTH and cortisol responses in 12, blunted responses in 4 and no response in 2 cases. No reduction in ACTH and cortisol levels after suppression tests was observed in 4 of 29 patients after dexamethasone (1 mg overnight) or in 6 of 29 after loperamide. The 4 patients who were unresponsive to both tests did not show any further inhibition after high-dose dexamethasone administration, had low plasma ACTH levels and showed impaired or absent responses to the CRH test: they were diagnosed as affected with preclinical Cushing's syndrome. An exogenous ACTH test performed in 30 patients caused a normal cortisol rise. Basal mean 17-hydroxyprogesterone (17-OHP) levels were not different from those in normal subjects. After ACTH the 17-OHP rate increase was higher than in normal subjects (17-OHP(30–)/30 min = 0.31 ±0.04 vs 0.07 ± 0.01 nmol·1−1·min−1; mean±SEM, p < 0.01); in particular, this parameter was elevated in 18 of 30 patients (17-OHP(30–0)/30 min range = 0.23–1.07 vs 0.01–0.19 nmol·1−1·min−1 in normal subjects). In a subset of 11 patients, serum markers of bone (bone-GLA protein (BGP) and carboxyterminal cross-linked telopeptide of type I collagen (ICTP) and collagen turnover (aminoterminal propeptide of type III procollagen (PIIINP)) were significantly (p < 0.01) lower than in normal subjects: in particular, in 2 preclinical Cushing's patients they were markedly reduced and rose after unilateral adrenalectomy. Of these 2 patients who underwent surgery, 1 showed a secondary hypoadrenalism. The histological study in 7 operated patients revealed the presence of benign adenoma in 4 cases and carcinoma, myelolipoma and hematoma in the others. In conclusion, in patients with incidentalomas endocrine testing is recommended because about two-thirds of them show subtle signs of adrenal overactivity. In patients with enzymatic defects of steroidogenesis a surgical approach is not suggested. On the contrary, the existence of a preclinical Cushing's syndrome has to be investigated carefully and followed up in order to disclose the possible appearance of clinical and/or metabolic features induced by the hypercortisolism and to suggest a surgical treatment. B Ambrosi, Institute of Endocrine Sciences, Ospedale Maggiore, IRCCS, via F Sforza 35, 20122 Milan, Italy
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The determination of ACTH levels after CRH does not seem to add any advantage (1,23,34,35,37,38,46) to screening for SH.”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [37]
In the citing paper
“To simplify the diagnostic workout, other authors used the concomitant presence of at least two altered parameters of HPA axis activity for SH diagnosis (9, 18, 19, 21, 32, 37, 39, 40, 42, 47, 49, 52-54, 56, 60, 61).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [37]
Citations
Cited by
Sorted by citations
A Survey on Adrenal Incidentaloma in Italy
Mantero, F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.637 · Cited by 907
Incidentally Discovered Adrenal Masses*
Kloos, R. T., Gross, M. D., Francis, I. R., KOROBKIN, M. T., & Shapiro, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-4-460 · Cited by 869
The clinically inapparent adrenal mass: update in diagnosis and management
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., & Bornstein, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0031 · Cited by 781
“7 69 0 6 Ambrosi 1995 (53) Italy 32 67 2–6.”
MethodPrevalence of adrenal incidentaloma in a contemporary computerized tomography series
Bovio, S., Cataldi, A., Reimondo, G., Sperone, P., Novello, S., Berruti, A., Borasio, P., Fava, C., Dogliotti, L., Scagliotti, G. V., et al. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344099 · Cited by 712
Prevalence and natural history of adrenal incidentalomas
Barzon, L., Sonino, N., Fallo, F., Palu, G., & Boscaro, M. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490273 · Cited by 642
“Ambrosi et al. 1995 (51) 32 2.5 55 2.7 12.5 0 0 3.13 0 78.1 Aso & Homma 1992 (16) 210 0.7 53 4.9 3.3 23.3 3.3 4.29 1.4 36.7 Bardet et al. 1996 (52) 46 NR NR 2.6 6.5 4.4 0 4.35 2.2 69.6 Barzon et al. 2002 (53) 284 1.5 56 3.6 11.3 5.9 2.1 8.80 2.8 64.8 Bastounis et al. 1997 (54) 86 1.5 61 4.1 3.5…”
InfluentialAME Position Statement on adrenal incidentaloma
Terzolo, M., Stigliano, A., Chiodini, I., Loli, P., Furlani, L., Arnaldi, G., Reimondo, G., Pia, A., Toscano, V., Zini, M., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1147 · Cited by 523
“Different authors have used a number of criteria, often including a pair of altered test results (9, 13, 102, 104, 110, 116, 118, 119).”
Rossi, R., Tauchmanovà, L., Luciano, A., Martino, M. D., Battista, C., Viscovo, L. D., Nuzzo, V., & Lombardi, G. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.4.6515 · Cited by 416
Sherlock, M., Scarsbrook, A., Abbas, A., Fraser, S., Limumpornpetch, P., Dineen, R., & Stewart, P. M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa008 · Cited by 347
“A large number of clinical studies have investigated the characteristics of AIs (Table 3 (39, 40,42,46-84)).”
BackgroundAdrenal incidentaloma: a new cause of the metabolic syndrome?
Terzolo, M., Pia, A., Alì, A., Osella, G., Reimondo, G., Bovio, S., Daffara, F., Procopio, M., Paccotti, P., Borretta, G., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8277 · Cited by 322
Cawood, T. J., Hunt, P. J., O'Shea, D., Cole, D., & Soule, S. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0234 · Cited by 300
Occult Cushing’s syndrome in type-2 diabetes
Catargi, B., Rigalleau, V., Poussin, A., Ronci-Chaix, N., Bex, V., Vergnot, V., Gin, H., Roger, P., & Tabarin, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030254 · Cited by 287
Subclinical Cushing’s syndrome
Reincke, M. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70115-8 · Cited by 285
Diagnosis and Treatment of Subclinical Hypercortisolism
Chiodini, I. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2722 · Cited by 279
“The determination of ACTH levels after CRH does not seem to add any advantage (1, 23, 34, 35, 37, 38, 46) to screening for SH.”
BackgroundInfluentialLong-term follow-up study of patients with adrenal incidentalomas.
Libe, R., Dall'Asta, C., Barbetta, L., Baccarelli, A., Beck-Peccoz, P., & Ambrosi, B. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470489 · Cited by 215
“As previously reported ( 6 , 9, 10), SCS was defined by the absence of signs or symptoms of hypercortisolism and by the presence of at least two of the following criteria: inadequate cortisol inhibition after 1 mg dexamethasone (cortisol levels $ 138 nmol/l), high or high – normal UFC excretion ($ 275 nmol/24 h), low…”
BackgroundMethodInfluentialSelf-citationSubclinical Cushing's syndrome in adrenal incidentaloma.
Terzolo, Osella, Alì, Borretta, Cesario, Paccotti, & Angeli, A. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00357.x · Cited by 198
“The appropriate management of patients with subclinical Cushing’s syndrome remains controversial (Reincke et al., 1992; Osellaet al., 1994; Ambrosi et al., 1995; Klooset al., 1995) in the absence of clear proof of the detrimental effects, if any, of silent hypercortisolism.”
BackgroundSubclinical Cushing’s syndrome in adrenal incidentalomas
Terzolo, M., Bovio, S., Reimondo, G., Pia, A., Osella, G., Borretta, G., & Angeli, A. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.008 · Cited by 179
“To circumvent the problem of false positivity of biochemical testing, some experts advocated that two concomitant alterations should be demonstrated to diagnose a patient who has subclinical Cushing’s syndrome [10,15,16,42].”
BackgroundInfluentialIncidentally Discovered Adrenal Tumors: Endocrine and Scintigraphic Correlates1
Barzon, L., Scaroni, C. M., Sonino, N., Fallo, F., Gregianin, M., Macrì, C., & Boscaro, M. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.1.4501 · Cited by 184
Development of overt Cushing’s syndrome in patients with adrenal incidentaloma
Barzon, L., Fallo, F., Sonino, N., & Boscaro, M. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460061 · Cited by 162
The Characteristics and Trends in Adrenocortical Carcinoma: A United States Population Based Study
Sharma, E., Dahal, S., Sharma, P., Bhandari, A., Gupta, V., Amgai, B., & Dahal, S. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3503w · Cited by 161
Anterior, posterior, or laparoscopic approach for the management of adrenal diseases?
Linos, D. A., Stylopoulos, N., Boukis, M., Souvatzoglou, A., Raptis, S., & Papadimitriou, J. M. (1997) · The American Journal of Surgery · doi:10.1016/s0002-9610(96)00408-4 · Cited by 139
Prevalence of Adrenal Carcinoma Among Incidentally Discovered Adrenal Masses
Terzolo, M. (1997) · Archives of Surgery · doi:10.1001/archsurg.1997.01430320116020 · Cited by 143
Di Dalmazi, G., Berr, C. M., Fassnacht, M., Beuschlein, F., & Reincke, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1401 · Cited by 139
Chidiac, R. M., & Aron, D. C. (1997) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70242-5 · Cited by 140
Subclinical Cushing’s syndrome: definition and management
Terzolo, M., Pia, A., & Reimondo, G. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04253.x · Cited by 131
Bülow, B., Ahrén, B., & the Swedish Research Council Study Group of Endocrine Abdominal Tumours (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.01028.x · Cited by 120
Management of adrenal incidentaloma
Terzolo, M., Bovio, S., Pia, A., Reimondo, G., & Angeli, A. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.04.001 · Cited by 113
Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study
Vassilatou, E., Vryonidou, A., Michalopoulou, S., Manolis, J., Caratzas, J., Phenekos, C., & Tzavara, I. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03492.x · Cited by 112
Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications.
Tsagarakis, S., Vassiliadi, D., & Thalassinos, N. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344133 · Cited by 113
DIAGNOSIS AND MANAGEMENT OF ADRENAL INCIDENTALOMAS
Barzon, L., & Boscaro, M. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67888-3 · Cited by 111
Masserini, B., Morelli, V., Bergamaschi, S., Ermetici, F., Eller-Vainicher, C., Barbieri, A. M., Maffini, M. A., Scillitani, A., Ambrosi, B., Beck-Peccoz, P., et al. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0485 · Cited by 106
Self-citationGlucocorticoids and neuroendocrine function
Cavagnini, F., Croci, M., Putignano, P., Petroni, M. L., & Invitti, C. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801284 · Cited by 105
Bernini, G., Moretti, A., Iacconi, P., Miccoli, P., Nami, R., Lucani, B., & Salvetti, A. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480213 · Cited by 105
“Secondly, in the case of surgical removal of the mass, perioperative cortisol replacement therapy is recommended to avoid the risk of adrenal insufficiency due to suppression of the contralateral normal gland (3, 6, 9, 11 ).”
BackgroundAron, D. C., & Howlett, T. A. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70124-9 · Cited by 90
Terzolo, M., Bovio, S., Pia, A., Conton, P. A., Reimondo, G., Dall’Asta, C., Bemporad, D., Angeli, A., Opocher, G., Mannelli, M., et al. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01959 · Cited by 89
“Several data from autopsy series (1, 2, 4), cross-sectional studies (9, 16 , 29) and case-control studies (19, 30) consistently point to an association between clinically inapparent adrenal adenoma and some manifestations of the metabolic syndrome (arterial hypertension, hyperglycemia, overweight).”
BackgroundSelf-citationSartorio, A., Conti, A., Ferrero, S., Giambona, S., Re, T., Passini, E., & Ambrosi, B. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1380146 · Cited by 84
Self-citationBiochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas.
Valli, N., Catargi, B., Ronci, N., Vergnot, V, Leccia, F., Ferriere, J., Chene, G., Grenier, N., Laurent, F., & Tabarin, A. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1440401 · Cited by 83
MANAGEMENT APPROACHES TO ADRENAL INCIDENTALOMAS
Mantero, F., & Arnaldi, G. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70119-5 · Cited by 83
Osella, G., Terzolo, M., Reimondo, G., Piovesan, A., Pia, A., Termine, A., Paccotti, P., & Angeli, A. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.10.4282 · Cited by 87
Tauchmanova, L., Rossi, R., Nuzzo, V, del Puente, A., Esposito-del Puente, A., Pizzi, C., Fonderico, F., Lupoli, G., & Lombardi, G. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1450241 · Cited by 79
Subclinical Cushing's syndrome.
Terzolo, M., Reimondo, G., Bovio, S., & Angeli, A. (2004) · Pituitary · doi:10.1007/s11102-005-4024-6 · Cited by 80
Tsagarakis, S., Roboti, C., Kokkoris, P., Vasiliou, V., Alevizaki, C., & Thalassinos, N. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00509.x · Cited by 75
“levels have also frequently been described in patients with adrenal incidentalomas and, in fact many authors have suggested that low DHEAS levels represent the most common abnormality in such patients (Osella et al., 1994; Ambrosi et al., 1995; Flecchiaet al., 1995).”
BackgroundSubclinical Cushing's syndrome in adrenal incidentalomas
Sippel, R. S., & Chen, H. (2004) · Surgical Clinics of North America · doi:10.1016/j.suc.2004.01.001 · Cited by 72
Adrenaloma: A Call for More Aggressive Management
Linos, D. A., Stylopoulos, N., & Raptis, S. (1996) · World Journal of Surgery · doi:10.1007/s002689900120 · Cited by 72
Systematic review of surgical treatment of subclinical Cushing's syndrome
Iacobone, M., Citton, M., Scarpa, M., Viel, G., Boscaro, M., & Nitti, D. (2015) · British journal of surgery · doi:10.1002/bjs.9742 · Cited by 74
Subclinical Cushing's syndrome
Terzolo, M., Bovio, S., Pia, A. R., Osella, G., Borretta, G., Angeli, A., & Reimondo, G. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000800013 · Cited by 67
“Increase in UFC excretion has been less frequently found [ 7 ,8,12,14,15] in agreement with the view that measurement of UFC has insufficient sensitivity to detect mild hypercortisolism [18].”
Graham, D. J., & McHenry, C. R. (1998) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(18)30243-6 · Cited by 66
Primary aldosteronism in normokalemic patients with adrenal incidentalomas
Bernini, G., Moretti, A., Argenio, G., & Salvetti, A. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460523 · Cited by 64
Bone metabolism and mass in women with Cushing’s syndrome and adrenal incidentaloma
Francucci, C. M., Pantanetti, P., Garrapa, G. G., Massi, F., Arnaldi, G., & Mantero, F. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01602.x · Cited by 65
Tsagarakis, S., Kokkoris, P., Roboti, C., Malagari, C., Kaskarelis, J., Vlassopoulou, V., Alevizaki, C. C., & Thalassinos, N. C. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00464.x · Cited by 63
“…decreased ACTH responsiveness to CRH and excessive urinary cortisol excretion have been detected with a decreasing order of frequency (Virkkala et al., 1989; Jockenhovel et al., 1992; Reincke et al., 1992; Osella et al., 1994; Ambrosi et al., 1995; Flecchia et al., 1995; Kasperlik-Zaluska, 1997).”
BackgroundMethodInfluentialEvaluation of hormonal function in a series of incidentally discovered adrenal masses.
Bondanelli, M., Campo, M., Trasforini, G., Ambrosio, M. R., Zatelli, M. C., Franceschetti, P., Valentini, A., Pansini, R., & Uberti, E. C. D. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90176-1 · Cited by 61
Subclinical Cushing’s syndrome
Leo, M. D., Cozzolino, A., Colao, A. A. L., & Pivonello, R. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2012.02.001 · Cited by 65
Falhammar, H., & Torpy, D. J. (2016) · Endocrine Practice · doi:10.4158/ep151085.ra · Cited by 63
Clinical Study of Adrenal Incidentaloma in Korea
Kim, H. Y., Kim, S. G., Lee, K. W., Seo, J. A., Kim, N. H., Choi, K. M., Baik, S. H., & Choi, D. S. (2005) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2005.20.4.303 · Cited by 62
Arnaldi, G., Masini, A., Giacchetti, G., Taccaliti, A., Faloia, E., & Mantero, F. (2000) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2000001000007 · Cited by 61
“2% in the largest clinical study) varies greatly depending on the diagnostic criteria and the screening methods used (3-5,18,20).”
BackgroundMethodInfluentialAdipokine levels and cardiovascular risk in patients with adrenal incidentaloma
Ermetici, F., Malavazos, A. E., Corbetta, S., Morricone, L. F., Dall’Asta, C., Romanelli, M. M. C., & Ambrosi, B. (2007) · Metabolism · doi:10.1016/j.metabol.2006.12.018 · Cited by 59
Self-citationOsella, G., Reimondo, G., Peretti, P., Alì, A., Paccotti, P., Angeli, A., & Terzolo, M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7178 · Cited by 54
“Different endocrine protocols were used to explore the function of the HPA axis in the literature, but most researchers suggest that two or more abnormalities should be present to define a truly relevant hypercortisolemic state (7, 9, 26, 33).”
MethodThe natural history of incidentally discovered adrenocortical adenomas: a retrospective evaluation.
Grossrubatscher, E., Vignati, F., Possa, M., & Loli, P. (2001) · Journal of Endocrinological Investigation · doi:10.1007/bf03343941 · Cited by 52
Terzolo, M., Ali, A., Osella, G., Reimondo, G., Pia, A., Peretti, P., Paccotti, P., & Angeli, A. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1420611 · Cited by 47
Ahn, S. H., Kim, J. H., Baek, S. H., Kim, H., Cho, Y. Y., Suh, S., Kim, B.-J., Hong, S., Koh, J.-M., Lee, S. H., et al. (2018) · Yonsei Medical Journal · doi:10.3349/ymj.2018.59.4.501 · Cited by 43
“Moreover, recent research has focused on subclinically hyperfunctional AIs showing a mild increase in hormone levels without other signs and symptoms of relevant diseases, since these conditions can eventually influence morbidity and mortality.(4,5) Accordingly, several study groups have sought to establish clinical p…”
Incidentally discovered adrenal masses
Kloos, R. T., KOROBKIN, M. T., Thompson, N. W., Francis, I. R., Shapiro, B., & Gross, M. D. (1997) · Cancer treatment and research · doi:10.1007/978-1-4615-6355-6_13 · Cited by 41
1,161 patients with adrenal incidentalomas: indications for surgery
Kasperlik-Zaluska, A. A., Otto, M., Cichocki, A. S., Rosłonowska, E., Slowinska-Srzednicka, J., Zgliczyński, W., Jeske, W., Papierska, L., Tołłoczko, T., Polański, J., et al. (2007) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-007-0238-6 · Cited by 38
“By definition, the patients with AI should not present any signs of hormone excess; however, detailed clinical, biochemical, and hormonal examinations could reveal some subtle abnormalities, named subclinical adrenal hyperfunction [7].”
BackgroundKann, P., Laudes, M., Piepkorn, B., Heintz, A., & Beyer, J. (2001) · Clinical Rheumatology · doi:10.1007/s100670170099 · Cited by 34
Dall’Asta, C., Barbetta, L., Libé, R., Passini, E., & Ambrosi, B. (2002) · Hormone Research in Paediatrics · doi:10.1159/000058381 · Cited by 34
“In recent years, the existence of several alterations of hormonal secretion in patients with ‘silent’ adrenal masses has been documented. Either subtle abnormalities in steroid biosynthesis or abnormal cortisol regulation leading to a ‘subclinical’ Cushing’s syndrome can be detected. Particularly, low dehydroepiandros…”
BackgroundSelf-citationLaparoscopic Adrenal Surgery: New Frontiers
Micali, S., Peluso, G., Stefani, S., et al. (2005) · Journal of Endourology · doi:10.1089/end.2005.19.272 · Cited by 34
Metabolism of glucocorticoids and mineralocorticoids in patients with adrenal incidentalomas
Maser‐Gluth, C., Reincke, M., Allolio, B., & Schulze, E. (2000) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2000.0300s3083.x · Cited by 32
The diagnosis and differential diagnosis of endogenous Cushing?s syndrome
Makras, P., Toloumis, G., Papadogias, D., Kaltsas, G., & Besser, M. (2006) · HORMONES · doi:10.14310/horm.2002.11189 · Cited by 31
Terzolo, M., Bossoni, S., Alı̀, A., Doga, M., Reimondo, G., Milani, G., Peretti, P., Manelli, F., Angeli, A., & Giustina, A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6531 · Cited by 31
“Some incidental adrenal adenomas show a functional autonomy even if the entity of hypercortisolism is relatively mild, because the patients do not present with a Cushingoid habit (5, 7, 8, 27 ).”
BackgroundMANAGEMENT APPROACHES TO ADRENAL INCIDENTALOMAS (ADRENALOMAS)
Linos, D. A. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70121-3 · Cited by 29
Biochemical bone turnover markers in hormonal disorders in adults: a narrative review
Szulc, P. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01269-7 · Cited by 30
Preclinical Cushing’s syndrome: Report of seven cases and a review of the literature
Morioka, M., Fujii, T., Matsuki, T., Jo, Y., Kobayashi, T., Tanaka, H. Y., Ohashi, T., & Kondo, K. (2000) · International Journal of Urology · doi:10.1046/j.1442-2042.2000.00154.x · Cited by 28
17-hydroxyprogesterone response to ACTH in bilateral and monolateral adrenal incidentalomas
Bernini, G., Brogi, G., Vivaldi, M. S., Argenio, G. R., Sgrò, M., Moretti, A., & Salvetti, A. (1996) · Journal of Endocrinological Investigation · doi:10.1007/bf03347878 · Cited by 27
Incidentally found adrenocortical carcinoma. A study of 21 patients
Kasperlik-Zaluska, A. A., Migdalska, B. M., & Makowska, A. M. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00170-1 · Cited by 28
Odagiri, E., Naruse, M., 寺崎, 和., YAMAGUCHI, N., Jibiki, K., Takagi, S., Tanabe, M., & Takano, K. (2004) · Endocrine Journal · doi:10.1507/endocrj.51.295 · Cited by 26
Imaging of adrenal incidentaloma: Our experience
Reginelli, A., Grezia, G. D., Izzo, A., D’Andrea, A., Gatta, G., Cappabianca, S., Squillaci, E., & Grassi, R. (2014) · International Journal of Surgery · doi:10.1016/j.ijsu.2014.05.029 · Cited by 24
Osella, G. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.2.604 · Cited by 24
The clinical evaluation of silent adrenal masses
Ambrosi, B., Passini, E., Re, T., & Barbetta, L. (1997) · Journal of Endocrinological Investigation · doi:10.1007/bf03347983 · Cited by 23
Self-citationBarzon, L., Maffei, P., Sonino, N., Pilon, C., Baldazzi, L., Balsamo, A., Del Maschio, O., Masi, G., Trevisan, M., Pacenti, M., et al. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03346358 · Cited by 24
Sixty Adrenal Masses of Large Dimensions: Hormonal and Morphologic Evaluation
BERNINI, G. P., Miccoli, P., Moretti, A., Vivaldi, M. S., Iacconi, P., & Salvetti, A. (1998) · Urology · doi:10.1016/s0090-4295(98)00026-0 · Cited by 24
Oki, Y., Hashimoto, K., Hirata, Y., Iwasaki, Y., Nigawara, T., Doi, M., Sakihara, S., Kageyama, K., & Suda, T. (2009) · Endocrine Journal · doi:10.1507/endocrj.k09e-194 · Cited by 22
BERNINI, G. P., Vivaldi, M. S., Argenio, G. F., et al. (1997) · Journal of Endocrinological Investigation · doi:10.1007/bf03347978 · Cited by 22
Tóth, M., Rácz, K., Adleff, V., Varga, I., Fütő, L., Jakab, C., Karlinger, K., Kiss, R., & Gláz, E. (2000) · Journal of Endocrinological Investigation · doi:10.1007/bf03343725 · Cited by 22
Adrenal incidentalomas and glucocorticoid autonomy
Aron, D. C. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00522.x · Cited by 20
Starker, L. F., Kunstman, J. W., & Carling, T. (2014) · Surgical Clinics of North America · doi:10.1016/j.suc.2014.02.008 · Cited by 21
Sartório, A., Conti, A., Ferrario, S., Passini, E., Re, T., & Ambrosi, B. (1996) · Postgraduate Medical Journal · doi:10.1136/pgmj.72.849.419 · Cited by 19
Self-citationDelibaşı, T., Karbek, B., Bozkurt, N. Ç., Çakır, E., Güngüneş, A., Ünsal, Ö. Ö., Aslan, M. S., & Çakal, E. (2015) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000053 · Cited by 15
Subclinical Cushing’s Syndrome
Beuschlein, F., & Reincke, M. (2005) · Springer eBooks · doi:10.1007/3-540-26861-8_7 · Cited by 15
Sadoul, J., Kézachian, B., Altare, S., Hadjali, Y., & Canivet, B. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1410238 · Cited by 16
Utility of plasma dehydroepiandrosterone sulphate determination in adrenal incidentalomas
Bernini, G. P., Argenio, G. F., Vivaldi, M. S., Moretti, A., Miccoli, P., Iacconi, P., Magagna, A., & Salvetti, A. (1998) · Journal of Endocrinological Investigation · doi:10.1007/bf03350772 · Cited by 14
Torlontano, M., Zingrillo, M., D’Aloiso, L., Ghiggi, M. R., Cerbo, A. D., Scillitani, A., Ciavarella, G., & Liuzzi, A. (1997) · Journal of Endocrinological Investigation · doi:10.1007/bf03348009 · Cited by 11
Harman, E., Karadeniz, M., Biray, C., Zengi, A., Çetinkalp, Ş., Özgen, G., Saygılı, F., Berdeli, A., Gündüz, C., & Yılmaz, C. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03345766 · Cited by 11
Tóth, M., Rácz, K., & Gláz, E. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.10.5187-4 · Cited by 10
Differential Diagnosis of Cushing’s Syndrome
Javorsky, B. R., Carroll, T. B., & Findling, J. W. (2011) · Endocrine updates · doi:10.1007/978-1-4614-0011-0_7 · Cited by 9
“Incidental adrenal adenomas occur in 4% of patients undergoing abdominal imaging and 5–20% of these individuals have biochemical hypercortisolism [78–86].”
BackgroundSubclinical Cushing's syndrome in adrenal incidentalomas--possible metabolic consequences.
Bohdanowicz-Pawlak, A., Szymczak, J., Waszczuk, E., Bolanowski, M., & Bednarek-Tupikowska, G. (2013) · PubMed · Cited by 9
Preclinical Cushing's syndrome in patients with an adrenal incidentaloma
Tjan‐Heijnen, V. C. G. (1998) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(97)00091-0 · Cited by 9
Preclinical Cushing's syndrome
Ambrosi, B., & Sartório, A. (1996) · Trends in Endocrinology and Metabolism · doi:10.1016/1043-2760(96)00031-8 · Cited by 9
Self-citationHa, J., Cho, H.-M., Lee, H., et al. (2019) · Hip & Pelvis · doi:10.5371/hp.2019.31.2.120 · Cited by 8
Angeli, A., Osella, G., Reimondo, G., & Terzolo, M. (2002) · KARGER eBooks · doi:10.1159/000061074 · Cited by 8
Karaköse, M., Karbek, B., Şahi̇n, M., Arslan, M. S., Topaloğlu, O., Erden, G., Demirci, T., Çalışkan, M., & Delibaşı, T. (2015) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000008 · Cited by 7
Majnik, J., Szücs, N., Patócs, A., Tóth, M., Balogh, K., Varga, I., Gláz, E., & Rácz, K. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03347517 · Cited by 6
Sartório, A., & Conti, A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.7.4978-1 · Cited by 6
Self-citation
Metadata
- Authors
- Ambrosi, B., Peverelli, S., Passini, E., Re, T., Ferrario, R., Colombo, P., Sartorio, A., & Faglia, G.
- Affiliations
- University of Milan (IT)
- Corresponding author
- Ambrosi, Bruno
- ORCID
- Colombo, Paolo
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 1995-04
- Volume
- 132
- Issue
- 4
- Pages
- 422-428
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2050960639
- Cited by
- 136
- References
- 0
- Citations by year
- 2024: 2 · 2023: 2 · 2020: 2 · 2019: 3 · 2018: 2 · 2016: 2 · 2015: 4 · 2014: 3 · 2013: 2 · 2012: 2
- FWCI
- 15.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- adrenal incidentaloma, preclinical Cushing's syndrome, endocrine function, ACTH, cortisol, dexamethasone suppression test, CRH stimulation test, 17-hydroxyprogesterone, Cushing's disease, adrenocortical function, adrenal insufficiency
- MeSH terms
- Adrenal Gland Neoplasms, Adrenal Glands, Adrenalectomy, Adrenocorticotropic Hormone, Adult, Aged, Androstenedione, Bone and Bones, Collagen, Corticotropin-Releasing Hormone, Cushing Syndrome, Diagnosis, Differential, Female, Humans, Hydrocortisone, Hydroxyprogesterones, Magnetic Resonance Imaging, Male, Middle Aged, Peptide Fragments, Procollagen, Radioimmunoassay, Tomography, X-Ray Computed, Osteocalcin, 17-alpha-Hydroxyprogesterone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
